Alli Sparks Reevaluation Of OTC Weight-Loss Indication
This article was originally published in The Tan Sheet
Executive Summary
FDA will revisit its thinking about weight loss as an OTC indication as the agency decides whether to allow Xenical to be sold without a prescription
You may also be interested in...
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy